Evidence map›Paper›PMID 28365892›Full record

ArticleSurgery today2017

Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.

Hiroaki Mieno, Keishi Yamashita, Kei Hosoda, Hiromitsu Moriya, Katsuhiko Higuchi, Mizutomo Azuma, Shouko Komori, Tsutomu Yoshida, Satoshi Tanabe, Wasaburo Koizumi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. History and emerging trends in chemotherapy for gastric cancer.Annals of gastroenterological surgery · 2021
    Review
  13. Article
  14. Article
  15. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Article
  16. Review
  17. Article
  18. Review
  19. Conversion surgery for gastric cancer patients: A review.World journal of gastrointestinal oncology · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hiroaki MienoDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan. hmieno@kitasato-u.ac.jp.
Keishi YamashitaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Kei HosodaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Hiromitsu MoriyaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Katsuhiko HiguchiDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Mizutomo AzumaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Shouko KomoriDepartment of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Japan.
Tsutomu YoshidaDepartment of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Satoshi TanabeDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Wasaburo KoizumiDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Natsuya KatadaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Masahiko WatanabeDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA triplet regimen of docetaxel, cisplatin, and S-1(DCS) is highly effective against metastatic gastric cancer. We performed this study to clarify the safety and efficacy of surgical resection in patients with initially unresectable gastric cancer, after down-staging or disease control was achieved by DCS chemotherapy.

methodsThe subjects of this retrospective study were 31 consecutive patients with initially unresectable gastric cancer, who underwent surgical resection between October, 2006 and December, 2012, after down-staging or disease control was achieved by DCS chemotherapy. We evaluated the clinicopathological factors and clinical outcomes and assessed radiographic response based on the RECIST criteria, not by central review.

resultBefore DCS chemotherapy, 18 patients had extra-regional lymph node metastasis, 5 had liver metastasis, 8 had macroscopic peritoneal metastasis, and 8 had pancreatic head invasion. Twenty-three (74.2%) of the 31 patients underwent R0 resection. Postoperative morbidity and mortality rates were 16.1 and 0%. During chemotherapy, grade 3/4 toxicities included neutropenia (54.8%), leukopenia (32.3%), and anemia (16.1%). Median progression-free survival and median overall survival (OS) were 42.1 and 56.1 months, respectively. These results were similar for all patients, except those with locally advanced disease alone. In the multivariate analysis for OS, ypN remained an independent negative prognostic factor (p = 0.018).

conclusionSurgical resection after DCS chemotherapy for initially unresectable gastric cancer was safe and provided a reasonable R0 resection rate and good mid-term survival.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCohort StudiesCombined Modality TherapyDocetaxelDrug CombinationsFemaleFollow-Up StudiesGastrectomyHumansMaleMiddle AgedNeoplasm StagingOxonic AcidCisplatinDocetaxelDrug CombinationsOxonic AcidS 1 (combination)TaxoidsTegafurConversion surgical therapyDCSGastric cancerPrognosisSafety

Identifiers

PMID28365892
OpenAlexW2600342108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.